Subject(s)
Humans , Male , Organometallic Compounds/therapeutic use , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/diagnostic imaging , Membrane Glycoproteins/therapeutic use , Radiopharmaceuticals/therapeutic use , Positron Emission Tomography Computed Tomography/methods , Prostatic Neoplasms/pathology , Neoplasm StagingSubject(s)
Membrane Glycoproteins/therapeutic use , Organometallic Compounds/therapeutic use , Positron Emission Tomography Computed Tomography/methods , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/radiotherapy , Radiopharmaceuticals/therapeutic use , Gallium Isotopes , Gallium Radioisotopes , Humans , Male , Neoplasm Staging , Prostatic Neoplasms/pathologyABSTRACT
The southern cattle fever tick, Rhipicephalus (Boophilus) microplus, is no doubt the most economically important ectoparasite of cattle globally. The inappropriate use of chemical acaricides has driven the evolution of resistance in populations of R. (B.) microplus. Anti-tick vaccines represent a technology that can be combined with acaricides in integrated control programs to mitigate the impact of R. (B.) microplus. The recombinant form of Bm86 antigen from the Campo Grande (rBm86-CG) strain of R. (B.) microplus was produced using the Pichiapastoris expression system to test its ability to immunoprotect cattle against tick infestation. Secretion of rBm86-CG by P. pastoris through the bioprocess reported here simplified purification of the antigen. A specific humoral immune response was detected by ELISA in vaccinated cattle. Immunoblot results revealed that polyclonal antibodies from vaccinated cattle recognized a protein in larval extracts with a molecular weight corresponding to Bm86. The rBm86-CG antigen showed 31% efficacy against the Campo Grande strain of R. (B.) microplus infesting vaccinated cattle. The rBm86-CG is an antigen that could be used in a polyvalent vaccine as part of an integrated program for the control of R. (B.) microplus in the region that includes Mato Grosso do Sul.
Subject(s)
Cattle Diseases/prevention & control , Cattle Diseases/parasitology , Membrane Glycoproteins/immunology , Membrane Glycoproteins/therapeutic use , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Rhipicephalus/immunology , Tick Infestations/veterinary , Vaccines/immunology , Animals , Cattle , Female , Male , Tick Infestations/prevention & control , Vaccines/therapeutic useABSTRACT
The southern cattle fever tick, Rhipicephalus (Boophilus) microplus, is no doubt the most economically important ectoparasite of cattle globally. The inappropriate use of chemical acaricides has driven the evolution of resistance in populations of R. (B.) microplus. Anti-tick vaccines represent a technology that can be combined with acaricides in integrated control programs to mitigate the impact of R. (B.) microplus. The recombinant form of Bm86 antigen from the Campo Grande (rBm86-CG) strain of R. (B.) microplus was produced using the Pichiapastoris expression system to test its ability to immunoprotect cattle against tick infestation. Secretion of rBm86-CG by P. pastoris through the bioprocess reported here simplified purification of the antigen. A specific humoral immune response was detected by ELISA in vaccinated cattle. Immunoblot results revealed that polyclonal antibodies from vaccinated cattle recognized a protein in larval extracts with a molecular weight corresponding to Bm86. The rBm86-CG antigen showed 31% efficacy against the Campo Grande strain of R. (B.) microplus infesting vaccinated cattle. The rBm86-CG is an antigen that could be used in a polyvalent vaccine as part of an integrated program for the control of R. (B.) microplus in the region that includes Mato Grosso do Sul.
O carrapato Rhipicephalus (Boophilus) microplus é, sem dúvidas, o ectoparasito economicamente mais importante para o gado a nível mundial. A utilização inadequada de acaricidas tem impulsionado a evolução da resistência em populações de R. (B.) microplus. Vacinas contra o carrapato representam uma tecnologia que pode ser combinada com acaricidas em programas de controle integrado para diminuir o impacto de R. (B.) microplus. A forma recombinante da Bm86 da cepa Campo Grande (rBm86-CG) de R. (B.) microplus foi produzido utilizando o sistema de expressão em Pichia pastoris para testar sua capacidade de imunoproteção ao gado contra a infestação de carrapatos. A secreção de rBm86-CG em P. pastoris pelo bioprocesso, simplificou a purificação do antígeno. A resposta imune humoral específica foi detectada por ELISA em soros de bovinos vacinados. Resultados de "imunoblot" revelaram que anticorpos policlonais de bovinos vacinados reconheceram uma proteína em extratos de larvas com um peso molecular correspondente à Bm86. O antígeno rBm86-CG mostrou eficácia de 31% contra a amostra CG de R. (B.) microplus utilizada para infestar os bovinos vacinados. Pelos resultados obtidos, concluímos que a rBm86-CG é um antígeno que pode ser usado em uma vacina polivalente, como parte de um programa integrado para o controle de R. (B.) microplus no estado do Mato Grosso do Sul, Brasil.
Subject(s)
Animals , Cattle , Female , Male , Cattle Diseases/parasitology , Cattle Diseases/prevention & control , Membrane Glycoproteins/immunology , Membrane Glycoproteins/therapeutic use , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Rhipicephalus/immunology , Tick Infestations/veterinary , Vaccines/immunology , Tick Infestations/prevention & control , Vaccines/therapeutic useABSTRACT
The southern cattle fever tick, Rhipicephalus (Boophilus) microplus, is no doubt the most economically important ectoparasite of cattle globally. The inappropriate use of chemical acaricides has driven the evolution of resistance in populations of R. (B.) microplus. Anti-tick vaccines represent a technology that can be combined with acaricides in integrated control programs to mitigate the impact of R. (B.) microplus. The recombinant form of Bm86 antigen from the Campo Grande (rBm86-CG) strain of R. (B.) microplus was produced using the Pichiapastoris expression system to test its ability to immunoprotect cattle against tick infestation. Secretion of rBm86-CG by P. pastoris through the bioprocess reported here simplified purification of the antigen. A specific humoral immune response was detected by ELISA in vaccinated cattle. Immunoblot results revealed that polyclonal antibodies from vaccinated cattle recognized a protein in larval extracts with a molecular weight corresponding to Bm86. The rBm86-CG antigen showed 31% efficacy against the Campo Grande strain of R. (B.) microplus infesting vaccinated cattle. The rBm86-CG is an antigen that could be used in a polyvalent vaccine as part of an integrated program for the control of R. (B.) microplus in the region that includes Mato Grosso do Sul.(AU)
O carrapato Rhipicephalus (Boophilus) microplus é, sem dúvidas, o ectoparasito economicamente mais importante para o gado a nível mundial. A utilização inadequada de acaricidas tem impulsionado a evolução da resistência em populações de R. (B.) microplus. Vacinas contra o carrapato representam uma tecnologia que pode ser combinada com acaricidas em programas de controle integrado para diminuir o impacto de R. (B.) microplus. A forma recombinante da Bm86 da cepa Campo Grande (rBm86-CG) de R. (B.) microplus foi produzido utilizando o sistema de expressão em Pichia pastoris para testar sua capacidade de imunoproteção ao gado contra a infestação de carrapatos. A secreção de rBm86-CG em P. pastoris pelo bioprocesso, simplificou a purificação do antígeno. A resposta imune humoral específica foi detectada por ELISA em soros de bovinos vacinados. Resultados de "imunoblot" revelaram que anticorpos policlonais de bovinos vacinados reconheceram uma proteína em extratos de larvas com um peso molecular correspondente à Bm86. O antígeno rBm86-CG mostrou eficácia de 31% contra a amostra CG de R. (B.) microplus utilizada para infestar os bovinos vacinados. Pelos resultados obtidos, concluímos que a rBm86-CG é um antígeno que pode ser usado em uma vacina polivalente, como parte de um programa integrado para o controle de R. (B.) microplus no estado do Mato Grosso do Sul, Brasil.(AU)
Subject(s)
Animals , Male , Female , Cattle , Cattle Diseases/prevention & control , /parasitology , Membrane Glycoproteins/immunology , Membrane Glycoproteins/therapeutic use , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Rhipicephalus/immunology , Tick Infestations/veterinary , Vaccines/immunology , Tick Infestations/prevention & control , Vaccines/therapeutic useABSTRACT
Antecedentes. Las infecciones recurrentes de las vías respiratorias altas y bajas representan los padecimientos más comunes de la edad pediátrica. Material y método. Estudio doble ciego, pareado y en paralelo. Se comparó la mejoría clínica y de laboratorio con un grupo de 44 pacientes control, a quienes se administró placebo, con un diagnóstico semejante, lo mismo que edades y distribución por sexo. Resultados. En el grupo de estudio, comparado con el de control (p<0.001 en todos los parámetros), a los 6, 9 y 12 meses posteriores al inicio del tratamiento hubo una disminución estadísticamente significativa del número de infecciones por año, duración de éstas y días de ausencia escolar. No hubo cambios estadísticamente significativos en las concentraciones de complemento hemolítico, C3, C4 e inmunoglobulinas IgA, IgG, IgM e IgE, cuando se compararon los valores basales y a los seis meses de iniciado el tratamiento. No se reportó reacción adversa a la administración oral de la glicoproteína de Klebsiella pneumoniae. Conclusión. Estos resultados sugieren que ésta puede usarse como coadyuvante en la prevención y tratamiento de pacientes con infecciones respiratorias bajas y altas recurrentes